Our development portfolio - Servier

OUR DEVELOPMENT PORTFOLIO

latest update 25 April 2019

Neuropsychiatric diseases
Immune-
Inflammatory diseases
Cardiovascular diseases
Diabetes
Cancer

Phase 1

Ischemic stroke

TAFIa inhibitor

Chronic heart failure

Anti Mir92a*

Haematological malignancies/Solid tumors

Mcl1 inhibitor

Haematological malignancies

Bcl2 inhibitor

Haematological malignancies

UCART 19

Haematological malignancies

Flotetuzumab (CD123xCD3)

Haematological malignancies

MPS1 inhibitor

Lung cancer, 2nd line

Liposomal Irinotecan

Cancer, 1st line

mPaCa / Liposomal Irinotecan

Colorectal cancer, 2nd line

Trifluridine/Tipiracil

Sjögren disease/UC

Anti IL7R

Phase 2

Venous leg ulcers

Osteoarthritis

ADAMTS-5 inhibitor

Post stroke

GABA A α5 antagonist

Phase 3

Chronic heart failure

Omecamtiv mecarbil

Type 2 diabetes

Exenatide implant

Colorectal cancer, 1st line

Trifluridine/Tipiracil

Autism

Bumetanide

filing

Gastric cancer

Trifluridine/Tipiracil

* Also tested in Wound Healing